drugset / Trial / NCT04677088

TCR-Redirected T Cell Treatment in Patients With Recurrent HBV-related Hepatocellular Carcinoma Post Liver Transplantation

NCT04677088

Phase 1 Unknown 7 enrolled Xiaoshun He Lion TCR Pte. Ltd. · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a single-arm and open-label study to assess the safety, tolerability and primary efficacy of the HBV specific T cell receptor (HBV/TCR) redirected T cell in patients with recurrent Hepatitis B virus (HBV) related hepatocellular carcinoma post liver transplantation.

Timeline

Start
2018-03-29
Primary completion
2020-02-18
Completion
2021-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject TCR-T cells Cell therapy 10000 cells/kg Intravenous
Subject TCR-T cells Cell therapy 5e+06 cells/kg Intravenous